{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:35:55Z","timestamp":1780554955957,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["133150\/2014-3"],"award-info":[{"award-number":["133150\/2014-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.clinre.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T20:44:38Z","timestamp":1552596278000},"page":"700-706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1"],"prefix":"10.1016","volume":"43","author":[{"given":"Vanessa Duarte","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nath\u00e1lia","family":"Delvaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo","family":"Brand\u00e3o-Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estev\u00e3o Portela","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo S\u00e9rgio Fonseca","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia Laura Lewis Ximenez","family":"de Souza Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Campello","family":"do Amaral Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2019.02.009_bib0005","unstructured":"WHO. Prevalence of chronically infected people with hepatitis C virus (HCV) worldwide, http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c; 2018 [Accessed 28th April 2018]."},{"issue":"2","key":"10.1016\/j.clinre.2019.02.009_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"Chen","year":"2006","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1016\/j.clinre.2019.02.009_bib0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2019.02.009_bib0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1478-3231.2011.02684.x","article-title":"An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region","volume":"32","author":"Nakano","year":"2012","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.clinre.2019.02.009_bib0025","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0016-5085(03)00394-9","article-title":"Side effects of therapy for chronic hepatitis C","volume":"124","author":"Russo","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.clinre.2019.02.009_bib0030","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.clinre.2019.02.009_bib0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1478-3231.2010.02411.x","article-title":"New direct-acting antivirals\u2019 combination for the treatment of chronic hepatitis C","volume":"31","author":"Asselah","year":"2011","journal-title":"Liver Int"},{"issue":"13","key":"10.1016\/j.clinre.2019.02.009_bib0040","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clinre.2019.02.009_bib0045","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clinre.2019.02.009_bib0050","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clinre.2019.02.009_bib0055","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clinre.2019.02.009_bib0060","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinre.2019.02.009_bib0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0034-1371007","article-title":"New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development","volume":"34","author":"Pawlotsky","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"6","key":"10.1016\/j.clinre.2019.02.009_bib0070","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/591141","article-title":"Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects","volume":"198","author":"Bartels","year":"2008","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.clinre.2019.02.009_bib0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.virol.2007.10.006","article-title":"Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient","volume":"370","author":"Cubero","year":"2008","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.clinre.2019.02.009_bib0080","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/hep.22773","article-title":"Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy","volume":"49","author":"Gaudieri","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clinre.2019.02.009_bib0085","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.clinre.2019.02.009_bib0090","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.clinre.2019.02.009_bib0095","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.antiviral.2005.12.003","article-title":"Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034","volume":"70","author":"Tong","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1016\/j.clinre.2019.02.009_bib0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","article-title":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","volume":"116","author":"Sarrazin","year":"2015","journal-title":"Antiviral Res"},{"issue":"5","key":"10.1016\/j.clinre.2019.02.009_bib0105","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","volume":"62","author":"Lenz","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2019.02.009_bib0110","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00705-010-0642-z","article-title":"Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naive patients","volume":"155","author":"Peres-da-Silva","year":"2010","journal-title":"Arch Virol"},{"issue":"1","key":"10.1016\/j.clinre.2019.02.009_bib0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/S0074-02762013000100002","article-title":"Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors","volume":"108","author":"Zeminian","year":"2013","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"12","key":"10.1016\/j.clinre.2019.02.009_bib0120","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/molbev\/mst197","article-title":"MEGA6: Molecular Evolutionary Genetics Analysis version 6.0","volume":"30","author":"Tamura","year":"2013","journal-title":"Mol Biol Evol"},{"issue":"3","key":"10.1016\/j.clinre.2019.02.009_bib0125","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/bioinformatics\/bth485","article-title":"The Los Alamos hepatitis C sequence database","volume":"21","author":"Kuiken","year":"2005","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.clinre.2019.02.009_bib0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2019.02.009_bib0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.clinre.2019.02.009_bib0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1128\/JCM.02371-13","article-title":"Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection","volume":"52","author":"Akuta","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.clinre.2019.02.009_bib0145","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3350\/cmh.2016.0107","article-title":"Management of direct antiviral agent failures","volume":"22","author":"Buti","year":"2016","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2019.02.009_bib0150","doi-asserted-by":"crossref","first-page":"e86413","DOI":"10.1371\/journal.pone.0086413","article-title":"HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in Sao Paulo, Brazil","volume":"9","author":"Nishiya","year":"2014","journal-title":"PLOS One"},{"issue":"12","key":"10.1016\/j.clinre.2019.02.009_bib0155","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciu696","article-title":"Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon\/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection","volume":"59","author":"Howe","year":"2014","journal-title":"Clin Infect Dis."},{"issue":"1","key":"10.1016\/j.clinre.2019.02.009_bib0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhep.2015.02.018","article-title":"Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders","volume":"63","author":"Jensen","year":"2015","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2019.02.009_bib0165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinre.2019.02.009_bib0170","article-title":"TMC-435 in patients infected with HCV genotype 1 who failed previous pegylated interferon\/ribavirin treatment: virologic analyses of the ASPIRE trial","author":"Lenz","year":"2012","journal-title":"49th Annual Meeting of the European Association for the Study of the Liver"},{"issue":"1-2","key":"10.1016\/j.clinre.2019.02.009_bib0175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2013.06.029","article-title":"Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies","volume":"444","author":"Barnard","year":"2013","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.clinre.2019.02.009_bib0180","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clinre.2019.02.009_bib0185","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1590\/S0074-02762012000200016","article-title":"Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs","volume":"107","author":"Peres-da-Silva","year":"2012","journal-title":"Mem Instit Oswaldo Cruz"},{"issue":"12","key":"10.1016\/j.clinre.2019.02.009_bib0190","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/AAC.00777-10","article-title":"Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors","volume":"54","author":"Bae","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.clinre.2019.02.009_bib0195","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment","volume":"87","author":"Bartels","year":"2013","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.clinre.2019.02.009_bib0200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2019.02.009_bib0205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1743-422X-10-57","article-title":"Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study","volume":"10","author":"Hoffmann","year":"2013","journal-title":"J Virol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740119300488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740119300488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:28:42Z","timestamp":1761895722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740119300488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S2210740119300488"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2019.02.009","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2019.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}